Patients with Growth-Related Disorders and Caregivers Prefer the Somapacitan Device to the Somatrogon Device: Results from a Randomized Crossover Study Assessing Device Preference and Ease of Use Following Simulated Injections

Autor: Akhtar S, Berg B, Medina J, Gonczi MN, Hamilton S, Hildebrand E, Kelepouris N, Neergaard JS, Sværke C, Ter-Borch G, Rasmussen NK

Publikováno v: Medical Devices: Evidence and Research, Vol Volume 17, Pp 427-439 (2024)

Shahid Akhtar,1 Birgitte Berg,2 Johan Medina,3 Maya Nicole Gonczi,4 Sophie Hamilton,5 Emily Hildebrand,4 Nicky Kelepouris,6 Jesper Skov Neergaard,7 Claus Sværke,8 Gitte Ter-Borch,2 Niklas Kahr Rasmussen3 1Devices & Digital Health, Novo Nordisk A/S,

Externí odkaz: https://doaj.org/article/6a5c5a7dfa7a42059cd6600944db9b4b

Disease and treatment burden of patients with haemophilia entering the explorer6 non-interventional study.

Autor: Windyga J; Department of Hemostasis Disorders and Internal Medicine, Laboratory of Hemostasis and Metabolic Diseases, Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Apte S; Sahyadri Speciality Hospital, Pune, India., Frei-Jones M; Pediatric Hematology-Oncology, Joe R. and Teresa Lozano Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA., Fujii T; Hiroshima University Hospital, Hiroshima, Japan., Lyu CJ; Yonsei University Severance Hospital, Seoul, Korea., Villarreal Martinez L; Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico., Sathar J; Hospital Ampang, Ampang, Selangor Darul Ehsan, Malaysia., Stasyshyn O; Institute of Blood Pathology and Transfusion Medicine, Lviv, Ukraine., Tran H; The Alfred Hospital, Melbourne, Victoria, Australia., Zozulya N; National Medical Center for Hematology, Moscow, Russia., Brown Frandsen R; Novo Nordisk A/S, Søborg, Denmark., Neergaard JS; Novo Nordisk A/S, Søborg, Denmark., Thaung Zaw JJ; Novo Nordisk A/S, Søborg, Denmark., Mahlangu J; University of the Witwatersrand and NHLS, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa.

Publikováno v: European journal of haematology [Eur J Haematol] 2024 Nov; Vol. 113 (5), pp. 631-640. Date of Electronic Publication: 2024 Jul 19.

Concizumab prophylaxis in persons with hemophilia A or B with inhibitors: patient-reported outcome results from the phase 3 explorer7 study.

Autor: Tran H; Ronald Sawers Haemophilia Centre, The Alfred Hospital, Melbourne, Victoria, Australia.; Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia., von Mackensen S; Department of Medical Psychology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany., Abraham A; Department of Hematology, Christian Medical College, Vellore, India., Castaman G; Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy., Hampton K; Department of Haematology, Royal Hallamshire Hospital, Sheffield, UK., Knoebl P; Division of Hematology and Hemostasis, Department of Medicine 1, Medical University of Vienna, Vienna, Austria., Linari S; Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy., Odgaard-Jensen J; Biostatistics HTA, Novo Nordisk A/S, Søborg, Denmark., Neergaard JS; Safety Surveillance CVD I, Novo Nordisk A/S, Søborg, Denmark., Stasyshyn O; Institute of Blood Pathology and Transfusion Medicine, Lviv, Ukraine., Thaung Zaw JJ; Medical & Science Rare Bleeding Disorders, Novo Nordisk A/S, Søborg, Denmark., Zulfikar B; Division of Pediatric Hematology-Oncology, Istanbul University Oncology Institute, Istanbul, Turkey., Shapiro A; Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, USA.

Publikováno v: Research and practice in thrombosis and haemostasis [Res Pract Thromb Haemost] 2024 Jun 17; Vol. 8 (4), pp. 102476. Date of Electronic Publication: 2024 Jun 17 (Print Publication: 2024).

HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HEMOPHILIA A OR B WITH INHIBITORS ON CONCIZUMAB PROPHYLAXIS: RESULTS FROM THE PHASE 3 EXPLORER7 STUDY

Autor: Shapiro, AD, Abraham, A, Linari, S, Neergaard, JS, Odgaard-Jensen, J, Zaw, JJT, Tran, H, Fabbron, GG

Publikováno v: In Hematology, Transfusion and Cell Therapy October 2023 45 Supplement 4:S458-S458

Understanding treatment burden in hemophilia: development and validation of the Hemophilia Treatment Experience Measure (Hemo-TEM).

Autor: Brod M; The Brod Group, 219 Julia Ave, Mill Valley, CA, USA. mbrod@thebrodgroup.net., Bushnell DM; Evidera | PPD, 7101 Wisconsin Ave, Bethesda, MD, USA., Neergaard JS; Novo Nordisk A/S, Vandtaarnsvej 112, Søborg, Denmark., Waldman LT; The Brod Group, 219 Julia Ave, Mill Valley, CA, USA., Busk AK; Novo Nordisk A/S, Vandtaarnsvej 112, Søborg, Denmark.

Publikováno v: Journal of patient-reported outcomes [J Patient Rep Outcomes] 2023 Feb 23; Vol. 7 (1), pp. 17. Date of Electronic Publication: 2023 Feb 23.